Managing FDA Recalls in 2026

FDA recalls are no longer rare, quiet, or purely operational events. Across food, drugs, medical devices, cosmetics, and consumer health products, recalls are increasing in frequency, expanding in scope, and drawing faster, more visible FDA oversight—often in near real time. As of 2025, FDA officials publicly acknowledged a sustained uptick in high‑risk (Class I) recalls, coupled with resource‑intensive monitoring and heightened scrutiny of how companies initiate, communicate, and close recalls.

For regulated companies, the message is clear: how a recall is managed can matter as much as why it started.

We’ll discuss here what has changed in FDA recall enforcement, where companies most often misstep, and how to materially alter outcomes.

The Modern FDA Recall Landscape: What’s Different Now

1. Recalls Are Still “Voluntary”—But Only in Name

Under longstanding FDA policy, recalls remain technically voluntary for most product categories, guided by 21 CFR Part 7.40–7.59. However, FDA has made clear that recall requests are reserved for urgent situations and that refusal or delay can quickly escalate to seizures, injunctions, registration suspension, or mandatory recalls where authorized by statute.

Recent congressional scrutiny and public enforcement actions confirm that FDA increasingly views recalls as a primary public‑health tool, not a cooperative courtesy. In practice, companies that hesitate or “debate the science” with FDA during a crisis often face longer recalls, broader scope, and reputational harm.

2. Mandatory Recall Authority Is Expanding—Quietly but Significantly

While mandatory recall authority has long existed for foods, infant formula, and medical devices, recent statutory and regulatory developments have expanded FDA’s leverage:

• Cosmetics: Under MoCRA, FDA issued draft guidance in December 2025 clarifying how it will implement mandatory cosmetics recall authority, including procedural expectations and opportunities for informal hearings.

• Medical Devices: FDA continues to exercise authority under Part 810 and has expanded early‑alert communications for device recalls, increasing public visibility before firms are fully operationally prepared.

• Food: FDA routinely uses mandatory recall authority as a backstop where firms resist or delay, particularly in Class I pathogen or allergen situations.

Critically, FDA often does not need to formally order a mandatory recall to achieve its effect. The threat alone shapes negotiations, timelines, and scope.

Where Companies Get Recall Management Wrong

Mistake #1: Treating Recalls as a Quality Issue—Not a Legal One

Many companies delegate recalls exclusively to quality or operations teams. But recalls trigger overlapping legal exposures: misbranding, adulteration, reporting failures, distribution chain liability, and follow‑on inspections. FDA evaluates recall strategy, communications, and effectiveness—not just root cause.

Mistake #2: Over‑ or Under‑Scoping the Recall

FDA expects a recall to be prompt, accurate, and appropriately scoped. Over‑broad recalls increase cost and brand damage; under‑inclusive recalls invite expanded FDA intervention and public warnings. Recall depth decisions are frequently second‑guessed during FDA effectiveness checks.

Mistake #3: Poor Recall Communications

FDA has repeatedly emphasized that recall communications must be clear, hazard‑appropriate, and free of marketing language. In 2025, FDA issued industry letters citing failures where recalled product remained on shelves weeks later due to weak communications across the supply chain. These failures resulted in enforcement follow‑ups and warning letters.

What Effective FDA Recall Management Actually Looks Like

Based on current FDA guidance, enforcement practice, and experience, successful recall management typically involves:

• Immediate legal assessment of health‑hazard classification and reporting obligations
• Strategic engagement with FDA recall coordinators before public communications are finalized
• Precision drafting of recall notices, press releases, and customer instructions consistent with 21 C.F.R. § 7.49
• Documented effectiveness checks aligned with FDA expectations
• Parallel preparation for follow‑on inspections, records requests, or enforcement actions

FDA monitors recalls closely—and terminating a recall is often the most challenging phase. Agency officials have publicly acknowledged that recall termination remains resource‑intensive and frequently delayed where documentation is inadequate.

Why FDA‑Focused Counsel Makes a Measurable Difference

FDA recalls sit at the intersection of law, science, operations, and public trust. Counsel experienced in FDA enforcement and inspection practice brings critical advantages:

• Understanding when FDA is likely to escalate—and how to prevent it
• Knowing how recall decisions affect future inspections, warning letters, and import exposure
• Managing communications so they satisfy FDA without unnecessarily amplifying litigation or press risk
• Coordinating recall strategy across food, drug, cosmetic, and device frameworks where companies operate in multiple FDA categories

It is important to treat recall management not as a one‑off crisis, but as part of a broader FDA risk strategy—designed to protect public health while preserving the company’s regulatory posture long after the recall is closed.

Final Takeaway: Recall Readiness Is No Longer Optional

In 2026, the question is no longer whether recalls will happen, but how quickly and competently a company responds when they do. FDA has made clear that delays, ambiguity, or missteps will be visible—and remembered.

Companies that treat recalls as a regulatory negotiation rather than a legal and strategic exercise, risk compounding the damage. Those that prepare for recalls by having recall plans in place, conducting mock recalls, and organizing teams early are far better positioned to control scope, shorten timelines, and emerge operationally intact.